TABLE 2.
Treatment | Cell Type | Gene Identifier | Log Fold Change | Adjusted Significance |
---|---|---|---|---|
Pravastatin–control | MDA-MB-231 | PTGS2* | −2.10 | 1.62E-11 |
MβCD–control | MDA-MB-231 | Lipocalin-2† | −0.96 | 6.19E-10 |
Pravastatin–MβCD | MDA-MB-231 | PTGS2 | −1.73 | 6.50E-06 |
Pravastatin–control | Calu-1 | ASNS‡ | 2.63 | 5.43E-18 |
MβCD–control | Calu-1 | ASNS | 2.87 | 1.18E-18 |
Pravastatin–MβCD | Calu-1 | RNU1-5§ | 1.42 | 1.75E-06 |
When the 50 genes with the highest fold change are ranked according to adjusted statistical significance these four genes are most impacted.
Prostaglindin-endoperoxide synthase-2 is a component of the pathways in cancer and small cell lung cancer pathways.
Steroid transport protein.
Asparagine synthetase.
snRNA component of the spliceosome.